Emalex Biosciences is Drug Discovery in United States that focus on neurological conditions business. Founded in 2008. They cover business area such as developer, biopharmaceutical drug, central nervous system disorder, rare and orphan neurological condition, central nervous system-relate disorder, fluency disorder, ecopipam, patient advocacy organization, medical researcher, novel treatment, rare disease.
2008
( 18 years old in 2026 )
Neurological Conditions
-
330 North Wabash
Suite 3500
Chicago, IL 60611
United States
Private
developerbiopharmaceutical drugcentral nervous system disorderrare and orphan neurological conditioncentral nervous system-relate disorderfluency disorderecopipampatient advocacy organizationmedical researchernovel treatmentrare disease
* We use standard office opening hours in near Emalex Biosciences's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Emalex Biosciences is Drug Discovery business from United States that founded in 2008 (18 years old in 2026), Emalex Biosciences business is focusing on Neurological Conditions.
Emalex Biosciences headquarter office and corporate office address is located in 330 North Wabash Suite 3500 Chicago, IL 60611 United States.
Emalex Biosciences was founded in United States.
In 2026, Emalex Biosciences is currently focus on neurological conditions sector.
Above is snippet of Google Trends for "neurological conditions" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Emalex Biosciences, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
